- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05258019
Site Preservation After Tooth Extraction
March 28, 2023 updated by: Nanfang Hospital of Southern Medical University
Prospective Clinical Study on Site Preservation of Alveolar Ridge After Tooth Extraction Before Dental Implantation
This study is mainly targeted affected teeth which could not be retained, and patients are willing to undergo implant repair at the later stage.
After teeth extraction, Geistlich Bio-Oss ® Particles or Bio-Oss ® Collagen are immediately implanted in the teeth extraction socket and covered with Bio-Gide ® collagen membrane for site preservation.Through postoperative follow-up, postoperative clinical and imaging objective indicators, combined with the subjective evaluation of surgeons and patients, and compared with conventional extraction treatment method, the study is aimed to evaluate the effectiveness of different site preservation of alveolar crest preservation, in order to reduce the alveolar bone width and height loss, effectively reduce alveolar bone absorption, or even achieve bone incrementation, thus to get the ideal site preservation effect, to improve the oral implant success rate, improve implant aesthetic score and patient satisfaction, provide more clinical standard reference of the clinical application of site preservation.
Study Overview
Status
Not yet recruiting
Study Type
Observational
Enrollment (Anticipated)
88
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Qi Liu, Ph.D.
- Phone Number: +86 20 62787153
- Email: liuqi0721@smu.edu.cn
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients who have teeth cannot be retained and are willing to do dental implant treatment at the teeth extration site.
Description
Inclusion Criteria:
- patients willing to performed site preservation with Geistlich Bio-Oss ® Particles + Bio-Gide ® collagen membrane after tooth extraction;
- patients willing to performed site preservation with Geistlich Bio-Oss ® Collagen + Bio-Gide ® collagen membrane after tooth extraction;
- patients willing to performed no site preservation after tooth extraction and only conventional healing.
Exclusion Criteria:
- patients unwilling to sign the informed consent form and the letter of authorization;
- patients has a potential systematic diseases;
- patients had previously been treated with radiation therapy;
- patients can not re-visit on time.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Geistlich Bio-Oss ® Particles + Bio-Gide ® collagen membrane
The first group of patients selected for site preservation will be performed with Bio-Oss ® Particles + Bio-Gide ® collagen membrane after tooth extraction
|
|
Geistlich Bio-Oss ® Collagen + Bio-Gide ® collagen membrane
The second group of patients selected for site preservation will be performed with Bio-Oss ® Collagen + Bio-Gide ® collagen membrane after tooth extraction
|
|
Conventional healing after tooth extraction, without site preservation
The third group of patients selected will be performed without site preservation after tooth extraction, and only conventional healing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in the alveolar crest height - central
Time Frame: up to 12 weeks after Dental extraction or site preservation surgery
|
The central alveolar bone height of the ideal implant site will be measured with CBCT at 3 months after tooth extraction or plus site preservation
|
up to 12 weeks after Dental extraction or site preservation surgery
|
|
Changes in the alveolar crest width - central
Time Frame: up to 12 weeks after Dental extraction or site preservation surgery
|
The central alveolar bone width of the ideal implant site will be measured with CBCT at 3 months after tooth extraction alone or plus site preservation
|
up to 12 weeks after Dental extraction or site preservation surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in the alveolar bone width - different depths
Time Frame: up to 12 weeks after Dental extraction or site preservation surgery
|
The width of the alveolar bone at 1,3,5, and 7mm below the alveolar crest will be measured with CBCT at 3 months after tooth extraction or plus site preservation
|
up to 12 weeks after Dental extraction or site preservation surgery
|
|
Changes in the alveolar bone height - different horizontal sites
Time Frame: up to 12 weeks after Dental extraction or site preservation surgery
|
The height of the alveolar bone will be measured at the mesial, central and distal of buccal and lingual of alveolar crest,and the midpoint of the mesial and distal of interproximal sites with CBCT at 3 months after tooth extraction alone or plus site preservation
|
up to 12 weeks after Dental extraction or site preservation surgery
|
|
Soft tissue thickness
Time Frame: up to 12 weeks after Dental extraction or site preservation surgery
|
The thickness of soft tissue will be measured at middle, central, and distal sites of both buccal-lingual sides,3mm from free gingival margin
|
up to 12 weeks after Dental extraction or site preservation surgery
|
|
Plaque index (PLI)
Time Frame: up to 12 weeks after Dental extraction or site preservation surgery
|
Each tooth extraction socket will be measured on 6 sites: buccal, central and lingual of both mesial-distal sides
|
up to 12 weeks after Dental extraction or site preservation surgery
|
|
Bleeding index (BI)
Time Frame: up to 12 weeks after Dental extraction or site preservation surgery
|
Each tooth extraction socket will be measured on 6 sites: buccal, central and lingual of both mesial-distal sides
|
up to 12 weeks after Dental extraction or site preservation surgery
|
|
Probing depth (PD)
Time Frame: up to 12 weeks after Dental extraction or site preservation surgery
|
Each tooth extraction socket will be measured on 6 sites: buccal, central and lingual of both mesial-distal sides
|
up to 12 weeks after Dental extraction or site preservation surgery
|
|
Phenotype assessment
Time Frame: up to 12 weeks after Dental extraction or site preservation surgery
|
Whether thick or thin gingival biotype will be detected by the transparency of the soft tissue while periodontal probing diagnosis
|
up to 12 weeks after Dental extraction or site preservation surgery
|
|
Pain degree
Time Frame: up to 12 weeks after Dental extraction or site preservation surgery.
|
The Visual Analogue Scale (VAS) pain score was evaluated: 0-10 (0: no pain; 1-3: slightly painful, acceptable; 4-6: painful, disrupt sleep, tolerable; 7-10: very painful, untolerable, affect sleep and diet)
|
up to 12 weeks after Dental extraction or site preservation surgery.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
November 1, 2023
Primary Completion (Anticipated)
October 31, 2026
Study Completion (Anticipated)
October 31, 2027
Study Registration Dates
First Submitted
February 7, 2022
First Submitted That Met QC Criteria
February 17, 2022
First Posted (Actual)
February 28, 2022
Study Record Updates
Last Update Posted (Actual)
March 30, 2023
Last Update Submitted That Met QC Criteria
March 28, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Musculoskeletal Diseases
- Connective Tissue Diseases
- Stomatognathic Diseases
- Bone Diseases
- Tooth Diseases
- Stomatognathic System Abnormalities
- Bone Diseases, Developmental
- Tooth Abnormalities
- Osteochondrodysplasias
- Collagen Diseases
- Osteogenesis Imperfecta
- Anodontia
Other Study ID Numbers
- NFEC-2021-414
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteogenesis Imperfecta
-
Ultragenyx Pharmaceutical IncMereo BioPharmaCompletedOsteogenesis Imperfecta Type III | Osteogenesis Imperfecta Type IV | Osteogenesis Imperfecta, Type IUnited States, Canada, Denmark, France, United Kingdom
-
Nationwide Children's HospitalCompletedOsteogenesis Imperfecta Type III | Osteogenesis Imperfecta Type IIUnited States
-
Emory UniversityNot yet recruitingOsteogenesis Imperfecta | Osteogenesis Imperfecta Type III
-
Angitia Biopharmaceuticals Guangzhou LimitedNot yet recruitingA Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR) (EIR)Osteogenesis Imperfecta (OI)China
-
Istituto Ortopedico RizzoliRecruitingOsteogenesis Imperfecta | Osteogenesis Imperfecta (OI)Italy
-
Novartis PharmaceuticalsCompletedOsteogenesis ImperfectaUnited States
-
Shriners Hospitals for ChildrenNovartisCompleted
-
University Hospital, GhentUniversity Ghent; Brittle Bone Society; Osteogenesis Imperfecta FederationRecruiting
-
AmgenTerminatedOsteogenesis Imperfecta (OI)Canada, Czechia, Spain, United Kingdom, United States, Italy, Hungary, Australia, Belgium, France, Germany, Poland
-
Angitia Incorporated LimitedRecruitingOsteogenesis Imperfecta (OI)United States, France, Netherlands, Australia, Denmark, United Kingdom, Canada, Argentina